Elite in EGFR Positive Lung Cancer

Dr. Zofia Piotrowska

Oncology | Infectious Disease | Hematology
The General Hospital Corporation
55 Fruit St, 
Boston, MA 
Accepting New Patients
Offers Telehealth
Elite in EGFR Positive Lung Cancer
The General Hospital Corporation
55 Fruit St, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Zofia Piotrowska is an Oncologist and an Infectious Disease provider in Boston, Massachusetts. Dr. Piotrowska is rated as an Elite provider by MediFind in the treatment of EGFR Positive Lung Cancer. Her top areas of expertise are EGFR Positive Lung Cancer, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Tissue Biopsy. Dr. Piotrowska is currently accepting new patients.

Her clinical research consists of co-authoring 84 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 23 articles and participated in 4 clinical trials in the study of EGFR Positive Lung Cancer.

Specialties
Oncology
Infectious Disease
Hematology
Licenses
Internal Medicine in MA
Hospital Affiliations
Massachusetts General Hospital
Brigham And Women's Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

THE GENERAL HOSPITAL CORPORATION
55 Fruit St, Boston, MA 02114

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Osimertinib, Selumetinib
Study Phase: Phase 2
A Phase 2 Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
A Phase 2 Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: June 10, 2025
Intervention Type: Drug
Study Drugs: EGF816, Gefitinib
Study Phase: Phase 2
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Cisplatin, Carboplatin
Study Phase: Phase 3
A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy
A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drug: CLN-081
Study Phase: Phase 1/Phase 2
Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
Enrollment Status: Terminated
Publish Date: November 22, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

84 Total Publications

Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.
Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 08, 2025
Similar Doctors
Elite in EGFR Positive Lung Cancer
Dr. Lecia V. Sequist
Oncology | Hematology
Elite in EGFR Positive Lung Cancer
Dr. Lecia V. Sequist
Oncology | Hematology

The General Hospital Corporation

40 2nd Ave, 
Waltham, MA 
 (10.3 miles away)
781-487-2900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lecia Sequist is an Oncologist and a Hematologist in Waltham, Massachusetts. Dr. Sequist is rated as an Elite provider by MediFind in the treatment of EGFR Positive Lung Cancer. Her top areas of expertise are EGFR Positive Lung Cancer, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Tissue Biopsy. Dr. Sequist is currently accepting new patients.

Geoffrey R. Oxnard
Elite in EGFR Positive Lung Cancer
Dr. Geoffrey R. Oxnard
Oncology
Elite in EGFR Positive Lung Cancer
Dr. Geoffrey R. Oxnard
Oncology

Evans Medical Foundation Inc

88 E Newton St, Evans 124, 
Boston, MA 
 (1.8 miles away)
617-638-6500
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Geoffrey Oxnard is an Oncologist in Boston, Massachusetts. Dr. Oxnard is rated as an Elite provider by MediFind in the treatment of EGFR Positive Lung Cancer. His top areas of expertise are EGFR Positive Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Tissue Biopsy. Dr. Oxnard is currently accepting new patients.

Elite in EGFR Positive Lung Cancer
Dr. Pasi A. Janne
Oncology
Elite in EGFR Positive Lung Cancer
Dr. Pasi A. Janne
Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (2.7 miles away)
617-632-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Pasi Janne is an Oncologist in Boston, Massachusetts. Dr. Janne is rated as an Elite provider by MediFind in the treatment of EGFR Positive Lung Cancer. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Lung Cancer, Lung Adenocarcinoma, and Tissue Biopsy. Dr. Janne is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Piotrowska's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile